Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY

^

Original-Research: Aiforia Technologies Oyj - from NuWays AG

17.04.2026 / 09:00 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.

---------------------------------------------------------------------------

Classification of NuWays AG to Aiforia Technologies Oyj

Company Name: Aiforia Technologies Oyj

ISIN: FI4000507934

Reason for the research: Update

Recommendation: BUY

Target price: EUR 3.8

Target price on sight of: 12 months

Last rating change:

Analyst: Julius Neittamo

Aiforia secures landmark hospital group as sole AI provider

Aiforia France has been selected as the sole AI partner for the French

government-backed PROSTIA project. The partnership expands Aiforia's

existing Assistance Publique-Hôpitaux de Paris (AP-HP) relationship from 2

to 7 hospitals, integrating its prostate cancer AI model into routine

clinical diagnostics.

We view this as a landmark clinical deployment and a validation of Aiforia's

market leadership in AI-assisted cancer diagnostics in Europe. PROSTIA is a

two-year project led by AP-HP, the largest public hospital group in Europe,

and funded by France's public investment bank Bpifrance, under France's EUR

54bn national France 2030 program.

Aiforia was selected as the only AI partner on PROSTIA, a testament to

Aiforia's techstack leadership, reinforcing an already strong moat. Hospital

system integrations carry significant upfront installation costs; new sites

must be onboarded, scanners connected, workflows reconfigured, and clinical

staff trained. Once embedded in a hospital's diagnostic workflow, switching

costs are high and the organisational inertia of large hospital groups like

AP-HP makes displacement by a competitor structurally difficult. The deal is

also significant, because France is the most important European market for

AI-assisted cancer diagnostics, based on size and state funding availability

for AI healthcare.

The contract value is not disclosed. However, it is estimated that 3k

biopsies a year represents the analysis of 30k whole slide images (WSIs).

Revenue per WSI varies from EUR 5 to EUR 10, translating to recurring revenue of

EUR 150k to EUR 300k annually at gross margins of ~75% and incremental EBITDA

margins of ~40% (eNuW), excl. significant one-off onboarding revenue from

integrating five new hospitals into the AI network. Noteworthy, the current

scope of PROSTIA is only for prostate cancer, but the objective is to expand

the framework to other high-prevalence cancers such as breast, lung,

gastric, and colorectal cancers. Thus, the long-run revenue potential from

AP-HP is only a fraction of what PROSTIA will generate in FY26.

As the goal of PROSTIA is to evaluate the medical, operational, and economic

benefits of AI pathology, the project can meaningfully shift procurement

from hospital budgets to state funding, for not only prostate but also other

types of common cancers, a key pivot for wider adoption of AI technology in

oncology. The structural urgency is real: pathologists are retiring much

faster than they're being replaced, and AI is increasingly the only credible

answer.

We do not make changes to our estimates. Our FY26e sales forecast of EUR 6m

already bakes in strong clinical wins and share-of-wallet expansion across

installed base. The PROSTIA contribution is consistent with our current

model assumptions. The more important read-through is qualitative: contract

wins of this calibre validate the growth runway expected in the hyperscale

years FY26-28. We remain convinced by the investment and reiterate our BUY

rating with a PT of EUR 3.80.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=514c968269fcdc7643ea04567928027d

For additional information visit our website:

https://www.nuways-ag.com/research-feed

Contact for questions:

NuWays AG - Equity Research

Web: www.nuways-ag.com

Email: research@nuways-ag.com

LinkedIn: https://www.linkedin.com/company/nuwaysag

Adresse: Mittelweg 16-17, 20148 Hamburg, Germany

++++++++++

Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss

bestimmter Börsengeschäfte.

Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben

analysierten Unternehmen befindet sich in der vollständigen Analyse.

++++++++++

---------------------------------------------------------------------------

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

View original content:

https://eqs-news.com/?origin_id=337c7ab1-3a26-11f1-8534-027f3c38b923&lang=en

---------------------------------------------------------------------------

2310206 17.04.2026 CET/CEST

°